PTTG Role in Ovarian Tumorigenesis and Matastasis

PTTG 在卵巢肿瘤发生和转移中的作用

基本信息

  • 批准号:
    7998178
  • 负责人:
  • 金额:
    $ 24.55万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-03-26 至 2012-12-31
  • 项目状态:
    已结题

项目摘要

Ovarian cancer is the fifth most commonly diagnosed cancer among women and the most frequent cause of death from gynecologic malignancies in the United States. Molecular mechanisms that initiate and support ovarian tumorigenesis are not well defined. We cloned a novel oncogene "PTTG" also known as securin from human testis and ovarian tumors and studied its function in tumorigenesis. PTTG is a multifunctional protein and is highly expressed in many tumors, including tumors of ovary. Introduction of PTTG into NIH3T3 and HEK293 cells induces cellular transformation and promotes tumor formation in nude mice, suggesting its strong oncogenic function. Notably, PTTG has been shown to inhibit separation of sister chromatids, and to increase the synthesis and secretion of bFGF, VEGF, and IL-8 as well as activate the expression of the oncogene, c-myc and PI3K/AKT signaling pathway, suggesting that the oncogenic activity of PTTG may involve induction of aneuploidy and chromosomal instability, increased angiogenesis, and production of growth promoting oncogene products. Down-regulation of PTTG expression in ovarian tumor cells in vitro and its deletion in animals (Knockout) results in reduction of tumor development, suggesting its important role in maintenance of cancer phenotype. The long-term objectives of this application are to understand the role of PTTG in ovarian tumorigenesis and validate PTTG as a molecular target for the development of anti- neoplastic agents. In this application we propose: i) to determine the effect of overexpression of PTTG in ovarian epithelial cells on cellular transformation and tumor development in nude mice; ii) to determine the effect of overexpression of PTTG in ovarian surface epithelial cells on ovarian tumor initiation, progression and metastasis in transgenic animals and determine mechanisms that support tumor growth and metastasis; and iii)to determine the effect of down-regulation of PTTG expression in ovarian tumor cells on tumor suppression and metastasis and determine mechanisms that lead to suppression of tumor growth and metastasis. These studies will provide critical information regarding the mechanisms of PTTG in ovarian tumorigenesis and metastasis and set up basis for the development of small molecules to inhibit PTTG function as anti-neoplastic agents. In addition transgenic animal model developed from our studies could enhance efforts aimed at developing new methods for detection, prevention, and treatment of ovarian cancer.
卵巢癌是女性第五种最常见的癌症,也是最常见的 在美国死于妇科恶性肿瘤。启动和支持的分子机制 卵巢肿瘤的发生还没有很好的定义。我们克隆了一个新的癌基因“PTTG”,也称为securin。 并研究其在肿瘤发生中的作用。PTTG是一种多功能蛋白质 并在许多肿瘤中高表达,包括卵巢肿瘤。在NIH3T3和NIH3T3中引入PTTG HEK293细胞诱导细胞转化并促进裸鼠成瘤,提示其 具有较强的致癌作用。值得注意的是,PTTG已被证明抑制姐妹染色单体的分离,并 促进碱性成纤维细胞生长因子、血管内皮生长因子和白介素8的合成和分泌,并激活血管内皮细胞的表达 癌基因、c-myc和PI3K/AKT信号通路,提示PTTG的致癌活性可能 包括诱导非整倍体和染色体不稳定,增加血管生成,以及产生 促生长癌基因产品。卵巢癌细胞PTTG表达下调的体外实验研究 在动物中它的缺失(基因敲除)导致肿瘤发展的减少,这表明它很重要 在维持癌症表型中的作用。这个应用程序的长期目标是理解 PTTG在卵巢肿瘤发生中的作用及作为抗卵巢癌分子靶点的验证 肿瘤剂。在本应用中,我们建议:i)确定PTTG过表达在 卵巢上皮细胞对裸鼠细胞转化和肿瘤发生的影响 卵巢表面上皮细胞PTTG过表达对卵巢肿瘤发生、发展的影响 以及转基因动物的转移,并确定支持肿瘤生长和转移的机制; 以及iii)确定卵巢肿瘤细胞中PTTG表达下调对肿瘤的影响 抑制和转移,并确定导致抑制肿瘤生长和转移的机制 转移。这些研究将为卵巢中PTTG的机制提供关键信息。 肿瘤的发生和转移,为开发抑制PTTG的小分子奠定基础 具有抗肿瘤作用。此外,根据我们的研究开发的转基因动物模型可以 加强努力,开发检测、预防和治疗卵巢癌的新方法。

项目成果

期刊论文数量(13)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Tumorigenic potential of pituitary tumor transforming gene (PTTG) in vivo investigated using a transgenic mouse model, and effects of cross breeding with p53 (+/-) transgenic mice.
  • DOI:
    10.1186/1471-2407-12-532
  • 发表时间:
    2012-11-20
  • 期刊:
  • 影响因子:
    3.8
  • 作者:
    Fong MY;Farghaly H;Kakar SS
  • 通讯作者:
    Kakar SS
Synergistic cytotoxic action of cisplatin and withaferin A on ovarian cancer cell lines.
Pituitary tumor transforming gene induces epithelial to mesenchymal transition by regulation of Twist, Snail, Slug, and E-cadherin.
  • DOI:
    10.1016/j.canlet.2011.06.033
  • 发表时间:
    2011-12-01
  • 期刊:
  • 影响因子:
    9.7
  • 作者:
    Shah, Parag P.;Kakar, Sham S.
  • 通讯作者:
    Kakar, Sham S.
Identification of metabolites in the normal ovary and their transformation in primary and metastatic ovarian cancer.
鉴定正常卵巢中的代谢产物及其在原发性和转移性卵巢癌中的转化。
  • DOI:
    10.1371/journal.pone.0019963
  • 发表时间:
    2011
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
    Fong MY;McDunn J;Kakar SS
  • 通讯作者:
    Kakar SS
Withaferin A (WFA) inhibits tumor growth and metastasis by targeting ovarian cancer stem cells.
  • DOI:
    10.18632/oncotarget.20170
  • 发表时间:
    2017-09-26
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Kakar SS;Parte S;Carter K;Joshua IG;Worth C;Rameshwar P;Ratajczak MZ
  • 通讯作者:
    Ratajczak MZ
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sham S. Kakar其他文献

Journal of Ovarian Research reviewer acknowledgement 2015
  • DOI:
    10.1186/s13048-016-0215-1
  • 发表时间:
    2016-02-18
  • 期刊:
  • 影响因子:
    4.200
  • 作者:
    Sham S. Kakar;Stefano Palomba;Benjamin K. Tsang;David T. Curiel
  • 通讯作者:
    David T. Curiel
Commentary: FSH and various forms of FSH receptors: distribution and their functions in gonads and extra-gonadal tissues
  • DOI:
    10.1186/s13048-021-00893-y
  • 发表时间:
    2021-10-30
  • 期刊:
  • 影响因子:
    4.200
  • 作者:
    Sham S. Kakar;Mariusz Z. Ratajczak
  • 通讯作者:
    Mariusz Z. Ratajczak
Ovarian cancer and the heart: pathophysiology, chemotherapy-induced cardiotoxicity, and new therapeutic strategies
  • DOI:
    10.1186/s13048-025-01636-z
  • 发表时间:
    2025-04-05
  • 期刊:
  • 影响因子:
    4.200
  • 作者:
    Megha Nair;Arun Samidurai;Anindita Das;Sham S. Kakar;Rakesh C. Kukreja
  • 通讯作者:
    Rakesh C. Kukreja
Withaferin A: a potential therapeutic agent against COVID-19 infection
  • DOI:
    10.1186/s13048-020-00684-x
  • 发表时间:
    2020-07-19
  • 期刊:
  • 影响因子:
    4.200
  • 作者:
    Alex R. Straughn;Sham S. Kakar
  • 通讯作者:
    Sham S. Kakar
PAF1-mediated transcriptional reprogramming confers docetaxel resistance in advanced prostate cancer
  • DOI:
    10.1016/j.canlet.2024.217355
  • 发表时间:
    2025-01-28
  • 期刊:
  • 影响因子:
  • 作者:
    Sakthivel Muniyan;Raghupathy Vengoji;Rama Krishna Nimmakayala;Parthasarathy Seshacharyulu;Balaji Perumalsamy;Zahraa Wajih Alsafwani;Sham S. Kakar;Lynette M. Smith;Nicole Shonka;Benjamin A. Teply;Subodh M. Lele;Moorthy P. Ponnusamy;Surinder K. Batra
  • 通讯作者:
    Surinder K. Batra

Sham S. Kakar的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sham S. Kakar', 18)}}的其他基金

Current Trends in Stem Cell Therapies
干细胞疗法的当前趋势
  • 批准号:
    10158506
  • 财政年份:
    2017
  • 资助金额:
    $ 24.55万
  • 项目类别:
Current Trends in Stem Cell Therapies
干细胞疗法的当前趋势
  • 批准号:
    9359106
  • 财政年份:
    2017
  • 资助金额:
    $ 24.55万
  • 项目类别:
PTTG Role in Ovarian Tumorigenesis and Matastasis
PTTG 在卵巢肿瘤发生和转移中的作用
  • 批准号:
    7538374
  • 财政年份:
    2007
  • 资助金额:
    $ 24.55万
  • 项目类别:
PTTG Role in Ovarian Tumorigenesis and Matastasis
PTTG 在卵巢肿瘤发生和转移中的作用
  • 批准号:
    7754388
  • 财政年份:
    2007
  • 资助金额:
    $ 24.55万
  • 项目类别:
PTTG Role in Ovarian Tumorigenesis and Matastasis
PTTG 在卵巢肿瘤发生和转移中的作用
  • 批准号:
    7179641
  • 财政年份:
    2007
  • 资助金额:
    $ 24.55万
  • 项目类别:
PTTG Role in Ovarian Tumorigenesis and Matastasis
PTTG 在卵巢肿瘤发生和转移中的作用
  • 批准号:
    7389540
  • 财政年份:
    2007
  • 资助金额:
    $ 24.55万
  • 项目类别:
MOLECULAR MECHANISMS OF HTTG IN OVARIAN TUMORS
HTTG 在卵巢肿瘤中的分子机制
  • 批准号:
    6174251
  • 财政年份:
    1999
  • 资助金额:
    $ 24.55万
  • 项目类别:
MOLECULAR MECHANISMS OF HTTG IN OVARIAN TUMORS
HTTG 在卵巢肿瘤中的分子机制
  • 批准号:
    2885542
  • 财政年份:
    1999
  • 资助金额:
    $ 24.55万
  • 项目类别:
MOLECULAR MECHANISMS OF HTTG IN OVARIAN TUMORS
HTTG 在卵巢肿瘤中的分子机制
  • 批准号:
    6454939
  • 财政年份:
    1999
  • 资助金额:
    $ 24.55万
  • 项目类别:
MOLECULAR MECHANISMS OF HTTG IN OVARIAN TUMORS
HTTG 在卵巢肿瘤中的分子机制
  • 批准号:
    6364393
  • 财政年份:
    1999
  • 资助金额:
    $ 24.55万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 24.55万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.55万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 24.55万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.55万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 24.55万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 24.55万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.55万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 24.55万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 24.55万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.55万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了